PMID- 32075402
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20200413
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Mar
TI  - Advanced lung adenocarcinoma with coexistent HER2 mutation and amplification and 
      response to afatinib: a case report.
PG  - 483-487
LID - 10.21037/apm.2020.02.14 [doi]
AB  - Human epidermal growth factor receptor 2 (HER2) mutation and amplification are 
      distinct molecular targets in lung cancer, but the specific targeted therapy for 
      their coexistence is undetermined. Personalized targeted therapy is based on 
      mutation type, with different mutations requiring different treatment. A 
      64-year-old Chinese woman was diagnosed with advanced lung adenocarcinoma. She 
      was determined as having insertion mutations in exon 20 of the HER2 gene (c.2326G 
      > TTGT) by the amplification refractory mutation system (ARMS) and HER2 gene 
      amplification (HER2/CEP17 ratio 2.6) by fluorescence in situ hybridization 
      (FISH). Thereafter, she was treated with afatinib as first-line therapy, to which 
      she responded. After 2 months, the tumor lesion decreased in size. Computed 
      tomography (CT) follow-up showed stable lung lesions, although she later 
      developed multiple brain metastases and subsequently died of brain failure. Lung 
      adenocarcinoma with coexistent HER2 mutation and amplification is relatively 
      uncommon and has no reported cases on targeted therapy. This case was important 
      because it showed effective response to afatinib and provides evidence to help 
      clinicians identify the therapeutic regimen for such patients.
FAU - Liu, Xiaona
AU  - Liu X
AD  - Department of Pathology, The First Hospital of Jilin University, Changchun 30021, 
      China.
FAU - Cao, Yuqing
AU  - Cao Y
AD  - Department of Pathology, The First Hospital of Jilin University, Changchun 30021, 
      China.
FAU - Li, Yuxin
AU  - Li Y
AD  - Department of Pathology, The First Hospital of Jilin University, Changchun 30021, 
      China.
FAU - Duan, Xiumei
AU  - Duan X
AD  - Department of Pathology, The First Hospital of Jilin University, Changchun 30021, 
      China. xmduan@jlu.edu.cn.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200214
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 41UD74L59M (Afatinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenocarcinoma/drug therapy/*genetics/pathology
MH  - Afatinib/*therapeutic use
MH  - Brain Neoplasms/secondary
MH  - ErbB Receptors
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*genetics/pathology
MH  - Middle Aged
MH  - Treatment Failure
OTO - NOTNLM
OT  - HER2 amplification
OT  - Human epidermal growth factor receptor 2 (HER2)
OT  - afatinib
OT  - case report
OT  - lung adenocarcinoma
OT  - mutation
EDAT- 2020/02/23 06:00
MHDA- 2020/04/14 06:00
CRDT- 2020/02/21 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
PHST- 2020/02/21 06:00 [entrez]
AID - apm.2020.02.14 [pii]
AID - 10.21037/apm.2020.02.14 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2020 Mar;9(2):483-487. doi: 10.21037/apm.2020.02.14. Epub 2020 
      Feb 14.